Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
ST. LOUIS, May 04, 2018 -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Monday, May 14, 2018 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2018 financial results conference call | |||||||
| When: | Monday, May 14th at 10:00 a.m. Eastern Time (7:00 a.m. PT) | |||||||
| Dial In Number: | To access the live call, dial 800-289-0438 (US and Canada) or 323-794-2423 (International) and give the participant pass code 7909480. | |||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com. | |||||||
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 21, 2018. To access the replay dial-in information, please click here. | |||||||
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
314-678-6100
[email protected]
